(DL)-3-O-Methyldopa

Names

[ Name ]:
(DL)-3-O-Methyldopa

[Synonym ]:
3-Methoxytyrosine
3-Methoxy-D,L-tyrosine
2-amino-3-(4-hydroxy-3-methoxyphenyl)propanoic acid
3-Methoxy-tyrosine
Tyrosine, 3-methoxy-
3-METHOXY-DL-TYROSINE
UNII:SO86T1OB2P
3-O-Methyldopa

Biological Activity

[Description]:

3-O-Methyl-DL-DOPA is an endogenous metabolite present in Cerebrospinal_Fluid that can be used for the research of Epilepsy, Purine Nucleoside Phosphorylase Deficiency and Aromatic L Amino Acid Decarboxylase Deficiency[1][2][3][4].

[Related Catalog]:

Research Areas >> Neurological Disease

[In Vitro]

Endogenous metabolites is defined as those that are annotated by Kyoto Encyclopedia of Genes and Genomes as substrates or products of the ~1900 metabolic enzymes encoded in our genome. It is clear in the body of literature that there are documented toxic properties for many of these metabolites[1].

[References]

[1]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720.

[2]. Darin N, et al. Mutations in PROSC Disrupt Cellular Pyridoxal Phosphate Homeostasis and Cause Vitamin-B6-Dependent Epilepsy. Am J Hum Genet. 2016 Dec 1;99(6):1325-1337.

[3]. Ormazabal A, et al. Pyridoxal 5'-phosphate values in cerebrospinal fluid: reference values and diagnosis of PNPO deficiency in paediatric patients. Mol Genet Metab. 2008 Jun;94(2):173-7.

[4]. Abdenur JE, et al. Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. Mol Genet Metab. 2006 Jan;87(1):48-53.

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Boiling Point ]:
407.3±45.0 °C at 760 mmHg

[ Molecular Formula ]:
C₁₀H₁₃NO₄

[ Molecular Weight ]:
211.214

[ Flash Point ]:
200.1±28.7 °C

[ Exact Mass ]:
211.084457

[ PSA ]:
92.78000

[ LogP ]:
0.08

[ Vapour Pressure ]:
0.0±1.0 mmHg at 25°C

[ Index of Refraction ]:
1.591

MSDS

Click to get detail MSDS

Safety Information

[ Risk Phrases ]:
22-36/37/38

[ Safety Phrases ]:
22-26-36/37/39

[ RIDADR ]:
NONH for all modes of transport

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Articles

Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.

Mov. Disord 26 , 543-546, (2011)

Oxidative stress is influenced by the thiol homeostasis, which determines the redox milieu. One of its components is Cysteinyl-glycine (Cys-Gly) generation, as its metabolic precursor is the free radi...

Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.

Clin. Neuropharmacol. 33(3) , 135-41, (2010)

The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluat...

Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.

Eur. J. Neurol. 19(6) , 820-6, (2012)

Catechol-O-methyltransferase inhibitors may be used to decrease levodopa requirement. The objective was to investigate whether the levodopa/carbidopa intestinal gel infusion dose can be reduced by 20%...

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.